Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare?) in Comparison to Oxybutynin for Overactive Bladder Patients.

Next Previous
Trial Profile

VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare?) in Comparison to Oxybutynin for Overactive Bladder Patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solifenacin (Primary) ; Oxybutynin
  • Indications Overactive bladder
  • Focus Adverse reactions; Registrational
  • Acronyms VECTOR
  • Sponsors Astellas Pharma

Most Recent Events

  • 17 Mar 2010 Results published in the Journal of Urology.
  • 30 Apr 2009 Results were presented at the American Urological Association Annual Meeting, according to a Astellas Pharma Canada media release.
  • 14 Jul 2008 Actual patient number is now 132 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top